Risky Business: PD-1 Immune Checkpoint Blockade in Thymic Epithelial Neoplasms - a podcast by American Society of Clinical Oncology (ASCO)

This podcast discusses the important risks and potential benefits of PD-1 immune checkpoint blockade in patients with thymic epithelial neoplasms.

Read the related article "Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial" on JCO.org

Further episodes of Journal of Clinical Oncology (JCO) Podcast

Further podcasts by American Society of Clinical Oncology (ASCO)

Website of American Society of Clinical Oncology (ASCO)